Status:
COMPLETED
Acute Revascularization Treatment in Ischemic Stroke Patients With COVID-19
Lead Sponsor:
Centre Hospitalier Universitaire Vaudois
Collaborating Sponsors:
Larissa University Hospital
Society of Vascular and Interventional Neurology
Conditions:
Ischemic Stroke
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
Case-series and cohort studies have shown the feasibility of reperfusion therapies in patients with ischemic stroke and COVID-19, but due to the absence of a contemporary control group of non-COVID-19...
Eligibility Criteria
Inclusion
- Consecutive ischemic stroke patients receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment) up to 24 hours since last time since well, and according to local treatment criteria
- From 1st of March 2020 (for Chinese Centers from 1st January 2020)
Exclusion
- Patients without a PCR- or antigen test within the first 7 days after treatment
- Patients with nosocomial SARS-CoV-2 infection after receiving acute recanalization treatment - PCR- or antigen test becoming positive more than 7 days after treatment
- Patients with "Suspect/ probable case of SARS-CoV-2 infection" according to the World Health Organization definition
- Symptomatic cases of SARS-CoV-2 infection with symptoms resolution more than 7 days before treatment
- Asymptomatic cases of SARS-CoV-2 infection with treatment performed more than 10 days after first positive test for SARS-CoV-2
Key Trial Info
Start Date :
April 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2021
Estimated Enrollment :
15128 Patients enrolled
Trial Details
Trial ID
NCT04895462
Start Date
April 30 2021
End Date
October 30 2021
Last Update
March 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lausanne University Hospital
Lausanne, Switzerland